Schaeffer's 43rd Anniversary Stock Picks in 2024

Analyst Downgrades: Nike Inc, Under Armour Inc, and BioMarin Pharmaceutical Inc.

Analysts downwardly revised their ratings and price targets on Nike Inc (NKE), Under Armour Inc (UA), and BioMarin Pharmaceutical Inc. (BMRN)

Jun 1, 2016 at 9:22 AM
facebook X logo linkedin


Analysts are weighing in on athletic apparel peddlers Nike Inc (NYSE:NKE) and Under Armour Inc (NYSE:UA), as well as drug stock BioMarin Pharmaceutical Inc. (NASDAQ:BMRN). Here's a quick roundup of today's bearish brokerage notes on NKE, UA, and BMRN.

  • Morgan Stanley cut its rating on NKE to "equal weight," citing the loss of U.S. market share and a potential sales slowdown. The brokerage firm also slashed its price target to $60 from $69. As a result, Nike Inc is pointed 3.2% lower in electronic trading, after settling Tuesday at $55.22 -- down 11.6% in 2016. If the stock doesn't bounce back soon, another round of downgrades could ensue. Currently, 20 of 26 analysts rate the technical underperformer a "buy" or better. Meanwhile, bearish betting continues to run rampant in NKE's options pits.

  • Rival UA is also struggling pre-market, down 3.6%, after the company cut its full-year earnings and revenue forecasts due to the bankruptcy of retailer Sports Authority. Responding to the news, Susquehanna, Jefferies, Goldman Sachs, Cowen and Company, and Credit Suisse all lowered their price targets on Under Armour Inc. Longer term, the stock has had a rough 2016, losing 9.4% at $37.73, prompting a rush of short selling. During the last two reporting periods, short interest on UA exploded nearly 40%, and now accounts for 7% of the stock's float.

  • After BMRN withdrew its market authorization application for Kyndrisa in Europe, the drug stock saw its price target cut to $115 at SunTrust Robinson and to $111 at Leerink. As such, the shares are pointed 2.9% lower ahead of the bell, after settling at $89.65 yesterday. While BioMarin Pharmaceutical Inc. could start June off on the wrong foot, it had a strong May, tacking on nearly 6%. Not surprisingly, options traders have been extremely bullish toward the stock. At the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), speculators have bought to open 173.75 calls for each put in the past 10 days -- a margin that hasn't been surpassed over the prior year.
Sign up now for Schaeffer's Opening View newsletter to get a head start on all the major pre-market news!
 

Nvidia and its powerful chips are the face of artificial intelligence.

But while everyone’s patting Nvidia on the back for record earnings…

It’s quietly moved on to the next phase of AI it plans to conquer…

Nvidia recently unveiled essential blueprints for this crucial $1 trillion pivot.

Click here now and find out about the three companies Nvidia absolutely needs to succeed in this vital new AI frontier. (ad)
schaeffer's opening view daily market newsletter

                                                                                                   
๐Ÿš€ Try Options Under $5 Trade Alerts 
Target +150% Profit w/RT Entry&Exit

                                                                                                    

 
 

                                                                                                   
This stock is paying its highest dividend
in 15 years . . . ๐Ÿ“ˆ (c/o Investors Alley)

                                                                                                    

 


                                                                                                   
Top 10 Investment Picks Poised For
Major Upside Before 2025 ๐Ÿ’ฐ
 (FREE)

                                                                                                    

 

join schaeffer's market recap daily stock marketnewsletter

 

                                               ad                                                  
Some of Nvidia’s partners have already
surged as much as 4,744%. This is next …

                                                ad